Articles tagged with Alzheimer Disease
Researchers have identified a protein 'off-switch' in the brain that regulates memory and learning. The Arc protein needs to be rapidly switched off after new information is received to remember and retain it.
Researchers identified a genetic link between SuperAgers and better memory retention, suggesting that therapies targeting the MAP2K3 gene could reduce age-related memory decline and Alzheimer's disease risk.
A team of researchers has discovered that the loss of BMI1 gene expression in the brains and neurons of patients with the common form of Alzheimer's disease is not a consequence of the disease, but rather its cause. This finding offers new hope for developing a cure by targeting the BMI1 gene.
A team of scientists has created a map of the molecular network in the aging brain, revealing two new Alzheimer's disease target genes that can be deleted or modified to treat the disease. The study provides a unique resource linking molecular changes in nearly 500 older brains to cognition and brain pathology.
Researchers at Salk Institute discovered that cells from older individuals had impaired mitochondria, leading to reduced energy production. This finding could reveal more about the link between mitochondrial dysfunction and age-related brain diseases.
Researchers at Washington University in St. Louis found an enzyme that breaks down plasmalogens, a phospholipid abundant in the heart and brain, shedding light on their role in Alzheimer's disease and other conditions.
The NIH summit recommends a precision medicine approach to Alzheimer's treatment and prevention, with a focus on developing interventions tailored to an individual's unique risk profile. The recommendations aim to build a collaborative research ecosystem capable of delivering urgently needed cures for people at all stages of the disease.
A novel computational approach has been developed to calculate optimal personalized brain stimulation treatment for Alzheimer's disease. The new framework incorporates patients' MRI scans and physiological brain signaling measurements to identify specific brain regions that would benefit from stimulation.
A large-scale study has identified three new genes linked to the risk of Alzheimer's disease, shedding light on the mechanisms underlying the condition. The findings, published in Translational Psychiatry, are based on genetic data from over 300,000 people and could pave the way for new approaches to treating the disease.
Researchers have identified a mutation that can reduce amyloid-beta plaque accumulation in mice, a hallmark of Alzheimer's disease. The study found that mice with the mutated APP gene had less amyloid-beta build-up, suggesting a potential therapeutic target.
Research by Dr. Fernanda De Felice reveals a disease mechanism common to Alzheimer's disease and Type 2 diabetes, leading to new strategies for preserving brain health. The discovery identifies a pathway causing inflammation in the brain, affecting insulin signaling and endoplasmic reticulum stress.
Researchers found that high homocysteine levels in mice lead to increased tau tangles, nerve cell death, and impaired learning and memory. The study suggests a potential link between hyperhomocysteinemia and neurodegenerative diseases, highlighting the need for further investigation into the role of 5-lipoxygenase in disease progression.
Researchers found that inheriting a variation in the PM20D1 gene increases the risk of developing Alzheimer's disease, making it an excellent candidate for clinical prevention trials. The study highlights the importance of international scientific collaboration and multidisciplinary research to tackle complex diseases like dementia.
Researchers at Indiana University found that rats can replay past events from memory using episodic memory replay. The study confirms the ability of animals to recall specific events and their order, which is essential for making sense of scenarios. This breakthrough could lead to more effective treatments for Alzheimer's disease.
A research study published at Purdue University identifies a small molecule SERCA activator that may improve memory and cognition, reducing cellular stress and preventing cell loss in neurons. The molecule corrects cells' calcium ion balance and represents a new therapeutic strategy for neurodegeneration drug development.
Researchers have identified protein clumping in the hearts of mice and people with heart failure, suggesting a potential link between the two conditions. The team used non-invasive PET scans to visualize the clumps, which could lead to advances in monitoring disease progression and testing new therapies.
A new Facebook app offers much-needed support to unpaid Alzheimer's caregivers through friendsourcing, a peer-to-peer support intervention. The study found that caregivers experience increased feelings of support when emotional and informational questions are answered by their Facebook friends.
As we age, the locus coeruleus, a key brain network controlling focus, weakens, causing older adults to be more easily distracted by irrelevant information. This disruption can lead to decreased attention and increased susceptibility to emotional arousal.
Researchers at DZNE found that blocking a particular receptor on astrocytes can normalize brain function and improve memory performance in mice models of Alzheimer's. This novel approach holds strong potential for treating the disease by targeting aberrant network dysfunctions in astrocytes.
UCLA researchers discovered a promising drug strategy blocking tau transmission, which could slow neurodegeneration in Alzheimer's disease. A small molecule called cambinol blocks the transfer of tau aggregates from cell to cell.
Researchers have created a rat model that can be used to study the buildup of amyloid plaques and vascular abnormalities in the brain, two key traits of Alzheimer's disease. The model, which uses human APP and PS1 proteins, has shown poor memory and learning in rats, similar to those observed in humans suffering from Alzheimer's.
A study found that starting tackle football before age 12 can lead to earlier onset of cognitive, behavior, and mood symptoms in athletes diagnosed with CTE. The average onset was 13 years earlier than expected. Participants were compared to those who started playing later.
Researchers found that music activates the salience network of the brain, which remains relatively functioning in individuals with Alzheimer's disease. The study suggests that personalized music programs may be an alternative route for communicating with patients who have lost contact with their environment.
A recent study indicates that dementia is being diagnosed later in life and lived for a shorter period, with possible contributing factors such as reduced stroke risk and increased vaccination rates. Researchers suggest other causes, including lower pollution levels and better nutrition, may also play a role.
Researchers found that trace amounts of beta-amyloid predicted future levels of tau and both preceded memory decline. Early intervention is crucial in slowing Alzheimer's disease progression by targeting anti-amyloid therapies before symptoms appear.
San Diego County has received a $1.3 million NIH grant to advance Alzheimer's research, aiming to find a treatment or cure for the disease. The funding will support a team of scientists in identifying prototype drugs that can bind to and modulate TREM2, a gene known to correlate with increased risk of developing late-onset Alzheimer's.
A new study found that individuals with malignant melanoma had a 61% lower risk of developing Alzheimer's disease compared to those without the condition. Basal cell and squamous cell carcinomas also showed significant reductions in AD risk, with correlations of 82% and 92%, respectively.
Researchers at IRB Barcelona have found covalently linked beta-amyloid dimers in the brains of patients with Alzheimer's disease. These dimers are preserved during tissue extraction and could serve as new biomarkers for early detection.
Researchers found that combining two approaches to reduce amyloid-beta improved spatial navigation and memory in a mouse model of Alzheimer's disease. The study suggests similar combination treatments may help patients with Alzheimer's disease in the future.
A new study reveals increased risks for Alzheimer's disease and suicidal tendencies among children and young adults living in polluted cities. Researchers detected abnormal proteins indicative of the disease as early as infancy, highlighting the need for preventative measures.
A new study found that losing one night of sleep led to an increase in beta-amyloid, a protein linked to Alzheimer's disease. The study also showed that participants with larger increases in beta-amyloid reported worse mood after sleep deprivation.
A protein involved in Alzheimer's disease may be a promising target for treating HIV-related neurological disorders. Elevated levels of BACE1 and Aβ oligomers were found in postmortem brain tissue of HIV-positive humans, suggesting similar mechanisms of neurotoxicity.
Long-term use of antiepileptic drugs is associated with a higher risk of developing Alzheimer's disease and dementia. Cognitive-impairing antiepileptic drugs increase the risk by 20% for Alzheimer's and 60% for dementia, with dose dependence observed.
Researchers investigated the association between angiotensin-converting enzyme (ACE) polymorphisms and cognitive change in late-onset Alzheimer's disease dementia. They found that ACE inhibitors slowed cognitive decline independently of blood pressure variations, particularly for APOE4- carriers with specific ACE genotypes. No function...
Researchers discovered that the apoE4 gene causes damage in human brain cells by altering its main structure and function. They found that adding a small molecule structure corrector eliminates signs of Alzheimer's disease, restores normal cell function, and improves survival in human apoE4 neurons.
A new blood test has been developed to detect early indicators of Alzheimer's disease, measuring the relative amounts of pathological and healthy amyloid-beta forms in the blood. The test was found to reliably detect signs of the disease on average eight years before diagnosis, with an overall diagnostic accuracy of 86%.
Researchers at UCLA have developed a new method that enables them to observe astrocytes' influence on nerve-cell communication in real time, shedding light on their role in neurological disorders such as Alzheimer's and Huntington's disease.
Caffeine found to exacerbate neuropsychiatric symptoms in Alzheimer's disease, impacting anxiety and cognitive flexibility. Long-term consumption worsened BPSD-like symptoms in mouse models.
A study found that evaluating and treating depression can improve or maintain cognitive functioning in some older patients with MCI. Approximately one third of participants who had progressed to MCI reverted back to normal cognition, suggesting that successful treatment may potentially reverse cognitive decline.
A recent study by the University of Eastern Finland found that initiating opioid analgesics reduces the use of antipsychotics and benzodiazepines in persons with Alzheimer's disease. This decrease was observed without worsening behavioural and psychiatric symptoms.
Researchers at WashU Medicine found a direct correlation between amyloid plaques and tau protein production in the brain. Targeting tau production may lead to new treatments for Alzheimer's disease.
Researchers found that tau production and secretion from nerve cells is an active process in the natural course of Alzheimer's disease. This may explain why experimental treatments targeting tau have had disappointing results. The study provides new insights into the role of tau kinetics in neurodegenerative diseases.
Scientists have discovered a beet compound that may help alleviate Alzheimer's symptoms by inhibiting the misfolding of proteins in the brain. The study found that betanin, a compound in beet extract, reduced oxidation of proteins associated with the disease, potentially slowing its progression.
Researchers found that beta-amyloid triggers calcineurin, leading to loss of dendritic spines and synapses in Alzheimer's disease. Rescuing synapses with extra Pin1 or FK506, an FDA-approved drug for transplant rejection, may slow disease progression.
Researchers discover vascular alterations in small blood vessels of mice with advanced Alzheimer's disease, affecting female mice more severely. The study finds correlations between vascular structure and function, anxiety levels, and cognitive functions.
Researchers found that genetically improving inhibitory interneurons and transplanting them into the brain of a mouse model with Alzheimer's disease can restore brain rhythms and cognition. This approach could lead to new treatment options for patients with Alzheimer's disease.
David A. Bennett's work in memory loss research has led to significant advancements in treating and preventing Alzheimer's disease and related disorders. The study's findings are shared globally to develop therapy and identify resilience characteristics.
Researchers found that altering Cdk5 activity made the brains of flies appear genetically older and their bodies to be about 20 days old. The study suggests that neurodegenerative disorders may accelerate the aging process, leading to earlier death and cognitive decline in affected individuals.
Researchers found that African Americans with a common genetic variation are 30% more likely to develop Alzheimer's disease dementia. In contrast, European Americans without the polymorphism are not at increased risk. Further studies are needed to understand why this correlation only appears in African-Americans.
A recent study published in Alimentary Pharmacology & Therapeutics found that long-term proton pump inhibitor (PPI) use does not increase the risk of hip fractures among people with Alzheimer's disease. The study followed a cohort of over 4,800 participants and analyzed their medication use.
A study found that excessive daytime sleepiness in older adults without dementia is associated with increased β-amyloid levels, a key biomarker for Alzheimer's disease. Disrupted sleep may contribute to β-amyloid accumulation and increase synaptic activity in the brain.
Researchers discover TREM2 receptor mediates anti-amyloid toxicity, potentially preventing or reducing neurodegenerative disorders like Alzheimer's. Boosting TREM2 levels in the brain may prevent disease progression and restore cognitive function.
Researchers profiled the epigenomic landscape of Alzheimer's disease brains, revealing a protective epigenetic link between aging and AD. The study found that certain normal aging changes in the epigenome may protect against AD, while dysregulated aging may induce disease-specific changes.
Researchers have developed a polygenic risk score to identify adults with mild cognitive impairment (MCI) in their 50s, who are at higher risk of developing Alzheimer's disease. The score correctly identified individuals with MCI and showed that those with cognitive deficits other than memory problems were more likely to have diabetes.
Researchers found that a compound enhanced protein trafficking reduced amyloid beta and Tau protein production in brain cells. The study suggests targeting endosomal network defects as a promising strategy against Alzheimer's disease.
The Alzheimer Prevention Trials Webstudy allows people 50+ to monitor cognitive health and join clinical trials aimed at preventing dementia. The free online platform addresses the major obstacle of delayed enrollment in Alzheimer's treatments.
A new study from UT Southwestern Medical Center found a correlation between traumatic brain injury and early-onset Alzheimer's disease. People who sustained concussions were diagnosed with dementia on average 2 1/2 years earlier than those without TBI.
A study investigated tau phosphorylation-related targets for Alzheimer's disease treatment, focusing on four kinases and one phosphatase. The model suggests the role of each enzyme in AD pathogenesis and identifies potential targets for therapy. This work builds upon InSysBio's quantitative systems pharmacology (QSP) modeling approach.
A Canadian study found that individuals close to their parent's onset age of Alzheimer's are more likely to have amyloid plaques in their brain. The research also suggests a stronger link between parental age, ApoE4 gene carriers, and increased disease risk.
Research reveals that individuals with Alzheimer's disease who die from the condition itself tend to have less hospitalization and ICU stays compared to those who die from other causes. This contrasts with those who receive fewer palliative care services during their final months.